Zeng, L., Ruan, Z., Yan, H., Qin, H., Zeng, Z., Zou, C., Huang, Z., Jiang, W., Dai, J., Xu, S., Song, L., Chen, Y., Zhang, Y., Zeng, F., Wei, S., Chen, S., Liu, L., Xiong, Y., Wang, Z., Deng, J., Zhang, X., Sun, Y., Yang, D., Zhou, C., Yang, H., Li, Y., Deng, L., Xu, Q., Fang, C., Chen, X., Wang, J., Li, T., Zhang, G., Zhou, H., Yang, N., Zhang, Y. (2025). PD-1/ PD-L1 bispecific antibody IBI318 combined with lenvatinib in advanced non-small cell lung cancer with acquired resistance to immune checkpoint inhibitors: a phase II trial. Nature Communications. https://doi.org/10.1038/s41467-025-67262-x